Login to Your Account



Pharma: clinic roundup


Monday, February 24, 2014
Janssen Research & Development LLC, of Raritan, N.J., part of Johnson & Johnson, started the CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) phase III, global, multicenter study of Invokana (canagliflozin).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription